<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114150">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01699867</url>
  </required_header>
  <id_info>
    <org_study_id>DxP 2012-02</org_study_id>
    <nct_id>NCT01699867</nct_id>
  </id_info>
  <brief_title>Computed Optical Margin Assessment for Breast Cancer Surgery</brief_title>
  <official_title>Computed Optical Margin Assessment for Breast Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diagnostic Photonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Diagnostic Photonics, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, prospective, open label study of approximately fifty (50)
      subjects at two (2) study sites, Johns Hopkins Hospital and Anne Arundel Medical Center.
      Patients scheduled to undergo lumpectomy will be recruited by the clinical investigators at
      the investigational site in accordance with the inclusion and exclusion criteria. The study
      period per subject is the time it takes to assess the ex vivo breast tissue samples using
      the study device during their lumpectomy.

      This trial compares intraoperative imaging analysis of breast tumor margins to results from
      post-operative histology. The study will evaluate the ability to identify margin status
      (sensitivity and specificity) of intraoperative imaging vs. final pathology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Ex vivo ISAM sensitivity and specificity</measure>
    <time_frame>one week after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The sensitivity and specificity of intraoperative imaging analysis to identify tumor on surgical specimen margins ex vivo when compared to blinded post-surgical histology findings.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interferometric Synthetic Aperture Microscopy</intervention_name>
    <description>Optical Coherence Tomography (Interferometric Synthetic Aperture Microscopy) will be used to image ex vivo breast tissue specimens.</description>
    <other_name>Optical Coherence Tomography</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women 18 years of age or older

          2. Signed informed consent form

          3. Women who have been histologically diagnosed with invasive ductal carcinoma or
             invasive lobular carcinoma of the breast prior to surgery

          4. Patients planning breast preservation and undergoing lumpectomy (partial mastectomy)
             procedure

        Exclusion Criteria:

          1. Multicentric disease (histologically diagnosed cancer in two different quadrants of
             the breast)

          2. Neoadjuvant systemic therapy

          3. All T4 tumors

          4. Previous radiation in the operated breast

          5. Prior surgical procedure in the same quadrant

          6. Implants in the operated breast

          7. Pregnancy

          8. Lactation

          9. Participating in any other investigational study for either drug or device which can
             influence collection of valid data under this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa K Jacobs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karyn Rhyder, RN</last_name>
    <phone>410-502-9693</phone>
    <email>kriedal1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristen Sawyer, M.S.</last_name>
      <phone>443-481-5749</phone>
      <email>ksawyer@aahs.org</email>
    </contact>
    <investigator>
      <last_name>Lorraine Tafra, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karyn Rhyder, R.N.</last_name>
      <phone>410-502-9693</phone>
      <email>kriedal1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa K Jacobs, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward W Gabrielson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>October 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lumpectomy, breast caner, invasive ductal carcinoma, invasive lobular carcinoma, optical coherence tomography, ISAM, tumor margin, imaging</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
